Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIxico Share News (IXI)

Share Price Information for Ixico (IXI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 7.00
Bid: 6.75
Ask: 7.25
Change: 0.00 (0.00%)
Spread: 0.50 (7.407%)
Open: 7.00
High: 7.00
Low: 7.00
Prev. Close: 7.00
IXI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Ixico pens deal to help develop a therapy for Parkinson's like diesease

Thu, 20th Oct 2016 11:01

(ShareCast News) - Shares in AIM-listed Ixico rose above 22% on Thursday, as the brain health company announced it had signed a $1.2m contract with a global pharmaceutical for imaging clinical trial services for a Parkinson's-like neurodegenerative disease.The project is for a second phase clinical study of patients in the early stages of progressive supranuclear palsy to develop a therapy that could prevent further degeneration, which will utilise the company's TrialTracker and Assessa digital platforms to collect and analyse MRI data from imaging centres across Europe and North America.The study, which is expected to be finished by 2019 with potential to be extended, is in line with the company's strategy to broaden the application of the Assessa platform to support the development of therapies, patients and to aid treatment decisions.Chief executive Derek Hill said the contract adds to the company's portfolio of clinical trials in progressive supranuclear palsy and validates the differentiation of its TrialTracker and Assessa digital platforms with a global pharmaceutical."We are pleased with the continued progress we are making to grow and evolve relationships within the pharmaceutical industry demonstrating our expertise across a range of neurological indications."Progressive supranuclear palsy is caused by the premature loss of nerve cells in certain parts of the brain, which over time this leads to difficulties with balance, movement, vision, speech and swallowing. Around 20,000 people have the disease in the US.Shares in Ixico were were up 22.13% to 28.70p at 1050 BST.
More News
22 May 2014 12:07

IXICO Wins Contracts For Huntington's Disease Clinical Trials

LONDON (Alliance News) - Brain health company IXICO PLC Thursday said it has won contracts for two separate clinical trials in Huntington's disease with "top 15" pharmaceutical companies, building on a third clinical study already underway on the disease. In a statement, IXICO said the two

Read more
16 Apr 2014 09:54

IXICO Awarded Development Contract By NHS England Initiative

LONDON (Alliance News) - IXICO PLC Wednesday said it has been awarded a development contract by The Small Business Research Initiative for Healthcare, an NHS England initiative, to cover phase 1 funding for the development of an online application designed to support dementia sufferers after they

Read more
16 Apr 2014 07:33

UK MORNING BRIEFING: RSA Loses UK & Western Europe Chief Executive

LONDON (Alliance News) - RSA Insurance Group said Wednesday the Chief Executive of the business which houses its troubled Irish operations has resigned in order to become Executive Chairman, underwriting and distribution, at business partner A J.Gallagher. The company said UK & Western Euro

Read more
20 Mar 2014 09:19

Thursday broker round-up UPDATE

Antofagasta: Deutsche Bank cuts target price from 770p to 735p and downgrades to sell. Investec cuts target price from 753p to 726p keeping its sell recommendation. Ashmore Group: HSBC Holdings lowers target price from 410p to 400p retaining its overweight rating. Avacta Group: Numis shifts target

Read more
11 Mar 2014 15:45

Standard Chartered non-exec builds company holding after profit decline

An Independent Non-Executive Director of Standard Chartered has this week upped his stake in the group by a quarter with the purchase of 2,500 shares. John Paynter, who was appointed to his role in 2008, bought the shares at 1,246.50p each for a total of £31,163, taking his total holding to 12,50

Read more
11 Mar 2014 15:07

DIRECTOR DEALINGS: Ixico Non-Executives Buy Shares

LONDON (Alliance News) - Ixico PLC said Tuesday that non-executive chairman Andy Richards had bought 13,700 shares at 78 pence each. Non-executive director Tim Sharpington bought 12,750 shares at 78.5 pence also on Tuesday. Following these purchases Richards has a 0.2% interest in the

Read more
7 Mar 2014 14:47

IXICO, VirtualScopics In International Commercial, Operational Alliance

LONDON (Alliance News) - Brain health company IXICO PLC Friday said it has entered into an international commercial and operational alliance with VirtualScopics Inc, a quantitative medical imaging provider. "The proposed alliance will provide the clinical trials industry with global operati

Read more
28 Feb 2014 15:59

IXICO Positive On Position Following Business Transition

LONDON (Alliance News) - IXICO PLC, the company formed when IXICO Ltd and Phytopharm PLC merged, said Friday that it believes it is strongly positioned in its core clinical trials and experimental medicine markets following the transition of its business. The company formally known as Phyto

Read more
18 Nov 2013 18:34

DIRECTOR DEALINGS: IXICO Non-Executive Director Buys Shares

Read more
18 Nov 2013 18:27

IXICO Non-Executive Director Buys Shares

Read more
1 Nov 2013 16:47

DIRECTOR DEALINGS: Ixico Executive Buys Shares

Read more
31 Oct 2013 14:05

DIRECTOR DEALINGS: IXICO CEO Buys 4,000 Shares

Read more
21 Oct 2013 12:45

DIRECTOR DEALINGS: IXICO Chairman Buys Shares

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.